Neovasc Inc. (NVCN)
Stock Price:
$2.38 USD
-0.12 (-4.80%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $2.40 +0.02 (0.84%) Oct 21, 6:03 PM
Key Info
| Market Cap |
53.90M |
| Revenue (ttm) |
2.09M |
| Net Income (ttm) |
-35.13M |
| Shares Out |
22.65M |
| EPS (ttm) |
-3.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$2.38 |
| Previous Close |
$2.50 |
| Change ($) |
-0.12 |
| Change (%) |
-4.80% |
| Day's Open |
2.49 |
| Day's Range |
2.33 - 2.50 |
| Day's Volume |
451,664 |
| 52-Week Range |
1.24 - 8.65 |
More Stats
| Market Cap |
53.90M |
| Enterprise Value |
64.18M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.65M |
| Float |
21.11M |
| EPS (basic) |
-5.40 |
| EPS (diluted) |
-3.40 |
| FCF / Share |
-8.64 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
51,350 |
| Short Ratio |
0.30 |
| Short % of Float |
0.24% |
| Beta |
3.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
25.76 |
| PB Ratio |
n/a |
| Revenue |
2.09M |
| Operating Income |
-30.05M |
| Net Income |
-35.13M |
| Free Cash Flow |
-24.22M |
| Net Cash |
-10.28M |
| Net Cash / Share |
-0.45 |
| Gross Margin |
86.74% |
| Operating Margin |
-1,436.26% |
| Profit Margin |
-1,679.30% |
| FCF Margin |
-1,157.52% |
| ROA |
-106.74% |
| ROE |
n/a |
| ROIC |
-381.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.67*
(264.29% upside)
Low
5.00
Current: $2.38
High
15.00
Target: 8.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 |
|---|
| Revenue | 2.09 | 1.75 | 5.39 | 9.51 | 9.93 | 14.37 | 11.75 | 7.82 | 1.55 | 1.52 |
| Revenue Growth | 19.6% | -67.54% | -43.35% | -4.2% | -30.9% | 22.33% | 50.24% | 405.69% | 1.87% | - |
| Gross Profit | 1.63 | 1.38 | 1.91 | 2.42 | 2.99 | 5.22 | 4.66 | 3.18 | 0.84 | 0.72 |
| Operating Income | -30.05 | -32.41 | -30.87 | -36.82 | -28.76 | -17.27 | -7.11 | -4.93 | -34.66 | -7.91 |
| Net Income | -35.13 | -108 | -21.63 | -86.49 | -26.73 | -18.15 | -6.75 | -0.35 | -34.26 | -7.83 |
| Shares Outstanding | 2.80 | 0.48 | 0.08 | 0.07 | 0.05 | 0.03 | 0.03 | 0.03 | 0.01 | - |
| Earnings Per Share | -5.40 | -76.26 | -265.37 | -1,282.10 | -410.00 | -330.00 | -140.00 | -10.00 | -2,940.00 | -1,590.00 |
| Operating Cash Flow | -23.97 | -22.79 | -139 | -39.79 | -21.28 | -8.06 | -4.68 | -2.04 | -8.48 | -6.44 |
| Capital Expenditures | -0.24 | 0.68 | -0.51 | 67.09 | -2.14 | -1.12 | -1.04 | -0.31 | -0.05 | -0.54 |
| Free Cash Flow | -24.22 | -22.12 | -139 | 27.29 | -23.43 | -9.18 | -5.72 | -2.35 | -8.53 | -6.98 |
| Cash & Equivalents | 5.29 | 9.24 | 17.51 | 92.95 | 55.03 | 15.54 | 3.40 | 5.86 | 2.55 | 3.29 |
| Total Debt | 15.57 | 14.62 | 20.01 | - | - | 0.17 | 0.24 | 0.28 | 0.44 | 0.46 |
| Net Cash / Debt | -10.28 | -5.37 | -2.50 | 92.95 | 55.03 | 15.36 | 3.16 | 5.58 | 2.11 | 2.83 |
| Assets | 10.11 | 13.33 | 23.48 | 98.81 | 61.23 | 20.37 | 7.44 | 8.80 | 4.82 | 5.69 |
| Liabilities | 24.55 | 21.66 | 58.68 | 114 | 3.23 | 2.34 | 1.82 | 1.35 | 1.67 | 1.51 |
| Book Value | -14.45 | -8.33 | -35.20 | -15.46 | 58.00 | 18.03 | 5.62 | 7.45 | 3.15 | 4.18 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neovasc Inc. |
| Country |
Canada |
| Employees |
110 |
| CEO |
Fredericus Antonius Colen |
Stock Information
| Ticker Symbol |
NVCN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: NVCN |
Description
Neovasc, a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.